Welcome to our dedicated page for Xtant Medical Holdings news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical Holdings stock.
Xtant Medical Holdings, Inc. reports developments as a medical technology company focused on surgical solutions for spinal and other orthopedic conditions. Its recurring updates include financial results, commercial activity in orthobiologics, and spinal implant systems used in complex spine, deformity, degenerative, wound care, and sports medicine applications.
Company news also covers product portfolio changes such as Trivium bone graft launches, U.S. distribution rights for HEMOBLAST Bellows, and completed divestitures involving Coflex, CoFix, and Paradigm Spine GmbH. These updates track how Xtant manages its biologics-focused portfolio, distribution channels, and surgical-product commercialization.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported a 5% increase in third quarter 2022 revenues, reaching $14.5 million, up from $13.8 million in Q3 2021. This growth was driven by a 12% rise in the biologics segment, attributed to the launch of OsteoFactor™ and OsteoVive® Plus products. Gross margin improved to 54.6%, while operating expenses rose to $9.8 million, resulting in a net loss of $2.4 million or $0.03 per share. The company expects to reach full operating capacity by Q1 2023, supported by a recent $9.75 million private placement.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its third-quarter financial results for the period ending September 30, 2022, on November 3, 2022, before market opening. A conference call led by CEO Sean Browne and CFO Scott Neils will follow at 9:00 AM ET to discuss these results. Investors are encouraged to participate via dial-in or web registration, with a replay available thereafter on the company's website.
Xtant Medical focuses on innovative surgical solutions for spinal disorders.
Xtant Medical Holdings (NYSE American: XTNT) announced the conclusion of a second tranche of a private placement, generating approximately $3 million from the sale of around 6.2 million shares and warrants. This follows an earlier tranche which raised approximately $6.75 million from 14.1 million shares and warrants. The total gross proceeds from both transactions are around $9.75 million. The funds will be utilized for working capital and corporate purposes. The Company plans to file a registration statement with the SEC for the resale of the common shares.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced the completion of the first tranche of a private placement, raising approximately $6.75 million by selling about 14.1 million shares and 3.5 million warrants. This financing is expected to enhance the company's growth strategy, as stated by CEO Sean Browne. A second closing tranche, anticipated in early October 2022, is projected to secure an additional $3 million. The company plans to use the funds primarily for working capital and corporate needs.
Xtant Medical Holdings (NYSE American: XTNT) has entered a securities purchase agreement to sell approximately $9.75 million in common stock and warrants to accredited investors, led by Stavros Vizirgianakis, who will become Non-Executive Chairman. The transaction involves the sale of around 20.3 million shares at $0.48 each, with a two-tranche closing process. The first closing is expected on August 26, 2022, with the second planned for October 2022. Proceeds will be used for working capital and corporate purposes. The securities are being offered under SEC exemptions.
Xtant Medical Holdings, Inc. (XTNT) reported a second quarter revenue of $15.3 million, marking a 2% increase year-over-year. The company’s biologics segment showed strong growth, up 8%, driven by new product demand. However, gross margin decreased to 54.8% from 63.5% due to higher costs and inventory charges. The net loss widened to $1.7 million, or $0.02 per share, compared to $0.7 million in Q2 2021. Despite challenges from supply chain issues, Xtant remains optimistic about future growth, with strategic initiatives gaining traction.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is set to announce its financial results for the second quarter ended June 30, 2022, on August 4, 2022, before market opening. The earnings conference call will occur at 9:00 AM ET, hosted by CEO Sean Browne and CFO Scott Neils. The company specializes in surgical solutions for spinal disorders, focusing on a broad range of orthobiologics and spinal implant systems. Following the call, a replay will be accessible on their website under ‘Investor Info’.
Xtant Medical Holdings reported a 3% revenue increase to $13.0 million for Q1 2022, up from $12.5 million in Q1 2021. The biologics segment saw a notable 13% year-over-year growth, driven by new product launches and expanded distribution. However, gross margin decreased to 58.3% from 64.5% due to higher production costs and a shift in sales mix. Operating expenses rose to $9.4 million, leading to a net loss of $2.2 million, compared to a loss of $29,000 in Q1 2021. Non-GAAP Adjusted EBITDA also worsened to a loss of $0.9 million.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has appointed Scott Neils as Chief Financial Officer, effective June 1, 2022. Neils, who has over 15 years of experience in public accounting and finance, previously served as the interim CFO since January 3, 2022, and as the company's Controller since August 2019. His extensive experience is expected to support the company’s growth strategy and mission of 'honoring the gift of donation.' The leadership change aims to strengthen financial management amid ongoing challenges in the medical technology sector.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its financial results for Q1 2022 on May 5, 2022, before market open. The conference call to discuss these results will be hosted by CEO Sean Browne and Interim CFO Scott Neils at 9:00 AM ET. Investors can access the call via dial-in or webcast. Xtant specializes in surgical solutions for spinal disorders, focusing on orthobiologics and spinal implant systems for complex spine procedures.